Values as of: 2025-06-07
COMMON STOCK | Drug Manufacturers - General |
Last Closing
USD 103Change
0.00 (0.00)%Market Cap
USD 127.02BVolume
0.10MAnalyst Target
N/AVerdict
Verdict
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Company Website : https://www.sanofi.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| RHHBF | Roche Holding AG |
N/A |
USD 248.88B |
| RHHBY | Roche Holding Ltd ADR |
N/A |
USD 248.79B |
| RHHVF | Roche Holding AG Participation |
N/A |
USD 248.79B |
| AZNCF | AstraZeneca PLC |
N/A |
USD 214.99B |
| CHGCY | Chugai Pharmaceutical Co Ltd A.. |
N/A |
USD 93.38B |
| DSNKY | Daiichi Sankyo Co Ltd ADR |
N/A |
USD 45.22B |
| ALPMF | Astellas Pharma Inc |
N/A |
USD 17.22B |
| ALPMY | Astellas Pharma Inc |
N/A |
USD 16.79B |
| RICFY | Recordati Industria Chimica e .. |
N/A |
USD 14.03B |
| CSPCY | CSPC Pharmaceutical Group Limi.. |
N/A |
USD 8.62B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| SEUC:PA | SSgA SPDR ETFs Europe I p.. | 0.32 % | 0.00 % |
N/A |
USD 0.84B |
| SYBD:F | SSgA SPDR ETFs Europe I p.. | 0.32 % | 0.00 % |
N/A |
USD 0.80B |
| SYBD:XETRA | SPDR® Bloomberg 0-3 Year.. | 0.32 % | 0.00 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Drug Manufacturers - General) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 8.31% | 34% | F | 55% | F | ||
| Dividend Return | 4.30% | 100% | F | 78% | C+ | ||
| Total Return | 12.61% | 50% | F | 61% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 5.66% | 58% | F | 59% | D- | ||
| Dividend Return | 4.19% | 87% | B+ | 58% | F | ||
| Total Return | 9.86% | 61% | D- | 61% | D- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 2.99% | 76% | C+ | 58% | F | ||
| Dividend Return | 19.27% | 85% | B | 49% | F | ||
| Total Return | 22.26% | 79% | B- | 59% | D- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 1.65% | 83% | B | 48% | F | ||
| Dividend Return | 5.38% | 73% | C | 50% | F | ||
| Total Return | 3.72% | 83% | B | 63% | D | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 11.85% | 90% | A- | 94% | A | ||
| Risk Adjusted Return | 45.38% | 93% | A | 83% | B | ||
| Market Capitalization | 127.02B | 79% | B- | 99% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
